Ryutaro Kotaki
Overview
Explore the profile of Ryutaro Kotaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kochayoo P, Moriyama S, Kotaki R, Thawornpan P, Malee C, Leepiyasakulchai C, et al.
PLoS Pathog
. 2025 Jan;
21(1):e1012866.
PMID: 39847574
Expansion of atypical memory B cells (aMBCs) was demonstrated in malaria-exposed individuals. To date, the generation of P. vivax-specific aMBCs and their function in protective humoral immune responses is unknown....
2.
Kotaki R, Moriyama S, Oishi S, Onodera T, Adachi Y, Sasaki E, et al.
Sci Transl Med
. 2024 Aug;
16(761):eadp9927.
PMID: 39167666
Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust induction of Omicron-specific humoral responses by Omicron-based booster vaccines. Here, we analyzed the specificity and neutralization activity of...
3.
Morino E, Mine S, Tomita N, Uemura Y, Shimizu Y, Saito S, et al.
NEJM Evid
. 2024 Feb;
3(3):EVIDoa2300290.
PMID: 38411447
BACKGROUND: Vaccination against mpox (formerly known as monkeypox), an infectious disease caused by the monkeypox virus (MPXV), is needed to prevent outbreaks and consequent public health concerns. The LC16m8 vaccine,...
4.
Simmons H, Finney J, Kotaki R, Adachi Y, Moseman A, Watanabe A, et al.
bioRxiv
. 2024 Jan;
PMID: 38168412
Influenza infection and vaccination impart strain-specific immunity that protects against neither seasonal antigenic variants nor the next pandemic. However, antibodies directed to conserved sites can confer broad protection. Here we...
5.
Finney J, Moseman A, Kong S, Watanabe A, Song S, Walsh Jr R, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
121(1):e2316964120.
PMID: 38147556
Phylogenetically and antigenically distinct influenza A and B viruses (IAV and IBV) circulate in human populations, causing widespread morbidity. Antibodies (Abs) that bind epitopes conserved in both IAV and IBV...
6.
Moriyama S, Anraku Y, Taminishi S, Adachi Y, Kuroda D, Kita S, et al.
Nat Commun
. 2023 Jul;
14(1):4198.
PMID: 37452031
SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging...
7.
Onodera T, Sax N, Sato T, Adachi Y, Kotaki R, Inoue T, et al.
Sci Adv
. 2023 Jun;
9(24):eadf0661.
PMID: 37315144
Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B) cells have variation in...
8.
Takano T, Sato T, Kotaki R, Moriyama S, Fukushi S, Shinoda M, et al.
Nat Commun
. 2023 Mar;
14(1):1451.
PMID: 36922492
The immunogenicity of mRNA vaccines has not been well studied when compared to different vaccine modalities in the context of additional boosters. Here we show that longitudinal analysis reveals more...
9.
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, et al.
iScience
. 2023 Jan;
26(2):105969.
PMID: 36687316
The immune responses to SARS-CoV-2 variants in COVID-19 cases are influenced by various factors including pre-existing immunity via vaccination and prior infection. Elucidating the drivers for upgrading neutralizing activity to...
10.
Kotaki R, Moriyama S, Takahashi Y
Inflamm Regen
. 2023 Jan;
43(1):4.
PMID: 36631890
The coronavirus disease 2019 (COVID-19) pandemic is ongoing because of the repeated emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, highlighting the importance of developing vaccines for variants...